Lazard Asset Management LLC Acquires 107,500 Shares of IQVIA Holdings Inc. $IQV

Lazard Asset Management LLC raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,866,537 shares of the medical research company’s stock after buying an additional 107,500 shares during the quarter. Lazard Asset Management LLC owned about 1.10% of IQVIA worth $294,145,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of IQV. Trust Co. of Toledo NA OH bought a new stake in IQVIA in the 2nd quarter valued at $39,000. J.Safra Asset Management Corp increased its holdings in shares of IQVIA by 208.6% in the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares during the last quarter. Rothschild Investment LLC lifted its position in shares of IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after buying an additional 124 shares in the last quarter. NewSquare Capital LLC boosted its stake in IQVIA by 185.3% during the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after buying an additional 189 shares during the last quarter. Finally, AllSquare Wealth Management LLC increased its stake in IQVIA by 68.6% in the 2nd quarter. AllSquare Wealth Management LLC now owns 312 shares of the medical research company’s stock worth $49,000 after acquiring an additional 127 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQV stock opened at $222.12 on Friday. The stock has a 50 day moving average price of $217.02 and a 200 day moving average price of $189.32. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $234.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The firm has a market capitalization of $37.83 billion, a P/E ratio of 30.47, a P/E/G ratio of 2.53 and a beta of 1.37.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on IQV. Morgan Stanley boosted their price target on shares of IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Evercore ISI boosted their price objective on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. BMO Capital Markets started coverage on IQVIA in a research note on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price objective for the company. Finally, UBS Group boosted their target price on IQVIA from $225.00 to $250.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $241.82.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is currently owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.